Premium
[P3–234]: THE RELATIONSHIP OF METABOLIC AND INFLAMMATORY BIOMARKERS TO SUBJECTIVE COGNITIVE COMPLAINTS IN A SAMPLE OF COGNITIVELY NORMAL MEXICAN‐AMERICANS
Author(s) -
Hall James R.,
Wiechmann April R.,
Johnson Leigh Ann,
Edwards Melissa,
O'Bryant Sid
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.06.1447
Subject(s) - medicine , biomarker , serum amyloid a , cognitive impairment , cognitive decline , cognition , interleukin 6 , gastroenterology , dementia , disease , inflammation , psychiatry , biology , biochemistry
on 1.5 T magnetic resonance images and normalized by the cerebellum gray matter uptake. Then, the association between (FBB) PET SUVR variables with TP and FP Ab40 and Ab42 levels was determined in SCD subjects. Obtained data were analyzed using correlations and linear regression-based methods. Finally, logistic regression and area under the receiver operating characteristic curve (AUROC) were calculated to evaluate the discrimination of brain amyloidosis. Results: (FBB) PET SUVR significantly correlated with TP Ab42/Ab40 ratio (r1⁄40.214, p1⁄42.59E-04, CI(95%) [-0.063 -0.019; logarithmic scale]. This observation resisted covariation with age, education, gender and APOE Ɛ4 carrier status. A total of 18 (9.05%) individuals had PET positive (FBB PET SUVR > 1.45). Multivariate analyses including age, APOE and logarithmic ratio TP Ab42/ Ab40 was the most discriminant model predicting brain amyloidosis (AUROC1⁄4 0.82). Conclusions: Brain and plasma Ab levels are partially correlated in individuals diagnosed with SCD. Ab measurements in plasma might help to identify SCD people with brain amyloidosis and to reduce the screening failure rate in ongoing pre-clinical AD studies. Independent replication of these findings is warranted.